κ1-Opioid binding sites are the dominant opioid binding sites in surgical specimens of human pheochromocytomas and in a human pheochromocytoma (KAT45) cell line

Kampa, Marilenna; Margioris, Andrew N.; Hatzoglou, Anastassia; Dermitzaki, Irene; Denizot, A.; Henry, J. F.; Oliver, Charles; Gravanis, Achille; Castanas, Elias

doi:10.1016/s0014-2999(98)00834-6

Cited by 15 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, naloxone and nor ‐BNI, a general opioid antagonist and a specific κ‐opioid antagonist, respectively, completely blocked it. Our data are in agreement with previously published data showing that adrenal chromaffin cells contain mainly κ‐and δ‐opioid receptors (Kampa et al, 1999). In addition, it has been shown that the opioids morphiceptin and U‐69593 enhance the staurosporine‐ or wortmannin‐induced apoptosis of primary neuronal cultures from embryonic cerebral hemispheres of chick brain and the F‐11κ7 cell line, an immortalized mouse neuroblastoma × dorsal root ganglion hybrid stably transfected to over‐express κ‐opioid receptors, in an antagonist‐reversible manner, suggesting that their effect is receptor mediated (Goswami et al, 1998).…”

Section: Discussionsupporting

confidence: 94%

“…PC12 cells retain this ability, but, in addition, they also produce large quantities of the prodynorphin‐deriving peptides, all strong κ‐opioid receptor agonists (Margioris et al, 1992). Interestingly, normal adrenal chromaffin cells, the PC12 cells, and most human pheochromocytomas possess mainly κ‐opioid receptors (Kampa et al, 1999). It thus appears that opioids may participate in local paracrine regulatory loops, finetuning the secretion of catecholamines, the proliferation and migration of chromaffin cells, and/or the communication between adrenal medulla and cortex (Venihaki et al, 1996 a , b ).…”

Section: Discussionmentioning

confidence: 99%

“…The majority of human pheochromocytoma cells (Kampa et al, 1999) as well as the most clones of PC12 cells, including ours, possess many types of opioid binding sites, but the dominant opioid receptor is the κ 1 type. Based on these data, the opioid antagonists used were the selective κ‐opioid antagonist nor ‐BNI (RBI, Natick, MA, U.S.A.) and the general opioid antagonist naloxone (Sigma).…”

Section: Methodsmentioning

confidence: 96%

See 2 more Smart Citations

Opioids Transiently Prevent Activation of Apoptotic Mechanisms Following Short Periods of Serum Withdrawal

Dermitzaki¹,

Chatzaki²,

Gravanis³

et al. 2000

Journal of Neurochemistry

View full text Add to dashboard Cite

Opioids exert a proapoptotic effect on several normal and tumoral cells. The aim of the present article was to examine the effect of opioids on the PC12 rat pheochromocytoma cell line, a model for the study of chromaffin cell apoptosis. These cells produce ␦-and -opioid agonists and their receptors. Our results were as follows: The -and ␦ 2 -opioid receptor agonists had a rapid but transient effect on apoptosis at 3 h, whereas opioids did not. The effect of opioids was reversible by the opioid antagonists naloxone and nor-binaltorphimine. The effect of opioids was protective, suppressing serum deprivation-induced apoptosis to ϳ50% of controls. The protective effect of opioids on PC12 apoptosis was measurable only under serum deprivation. The effect of opioids was remarkably reproducible and highly constant in timing, which did not appear to depend on the duration of the preceding serum deprivation. Finally, opioids prevented the elevation of the Bcl-2 and Bak proteins following serum deprivation to the levels attained by serum supplementation. Our combined data suggest that opioids protect PC12 cells from entering a state of induced apoptosis following serum deprivation.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 96%

See 1 more Smart Citation

Opioids Transiently Prevent Activation of Apoptotic Mechanisms Following Short Periods of Serum Withdrawal

Dermitzaki¹,

Chatzaki²,

Gravanis³

et al. 2000

Journal of Neurochemistry

View full text Add to dashboard Cite

show abstract

“…Expression of the KOR was confirmed by RT‐PCR and measurement of cAMP (Fig. 1c), which was in agreement with previous reports (Kampa et al . 1999; Dermitzaki et al .…”

Section: Resultssupporting

confidence: 92%

Leumorphin has an anti‐apoptotic effect by activating epidermal growth factor receptor kinase in rat pheochromocytoma PC12 cells

Lee

Kim

Hur

et al. 2005

Journal of Neurochemistry

View full text Add to dashboard Cite

Endogenous opioid peptides, found in the central and peripheral nervous systems, perform neuromodulatory roles, and display a wide range of functional and pharmacological properties in vitro and in vivo. In this study, we investigated the effects of prodynorphin gene products on intracellular signaling events and cell survival in rat pheochromocytoma PC12 cells. Leumorphin, but not other prodynorphin gene products including dynorphin A, b-neoendorphin and rimorphin (dynorphin B), increased cell viability in PC12 cells. The cytoprotective effect of leumorphin was dependent on the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways, but was insensitive to both naloxone, a general antagonist of the opioid receptor, and nor-binaltorphimine, a specific antagonist of the kappa opioid receptor. Moreover, a competition-binding assay clearly revealed that leumorphin had another binding site(s) in addition to that for the kappa opioid receptor. Interestingly, leumorphin induced activation of the epidermal growth factor receptor via a Srcdependent mechanism, which was proved to be responsible for the increased survival response. Flow cytometric and microscopic analysis showed that leumorphin rescued cells from serum deprivation-induced apoptosis. Collectively, we suggest that leumorphin prevents apoptosis via epidermal growth factor receptor-mediated activation of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways, which occur independent of the kappa opioid receptor.

show abstract

“…The presence of µ, δ and κ opioid receptors in bovine adrenal medulla and in human pheochromocytoma cell membranes has been demonstrated (Castanas et al, 1983(Castanas et al, , 1984Kampa et al, 1999). Considering that the role of opioids on catecholamine secretion in human pheochromocytoma has not been clearly demonstrated, we decided to analyze the existence of a possible regulation of catecholamine release by enkephalin in human pheochromocytoma cells in short-term cultures.…”

Section: Introductionmentioning

confidence: 97%

Possible autocrine enkephalin regulation of catecholamine release in human pheochromocytoma cells

et al. 2008

View full text Add to dashboard Cite

κ1-Opioid binding sites are the dominant opioid binding sites in surgical specimens of human pheochromocytomas and in a human pheochromocytoma (KAT45) cell line

Cited by 15 publications

References 30 publications

Opioids Transiently Prevent Activation of Apoptotic Mechanisms Following Short Periods of Serum Withdrawal

Opioids Transiently Prevent Activation of Apoptotic Mechanisms Following Short Periods of Serum Withdrawal

Leumorphin has an anti‐apoptotic effect by activating epidermal growth factor receptor kinase in rat pheochromocytoma PC12 cells

Possible autocrine enkephalin regulation of catecholamine release in human pheochromocytoma cells

Contact Info

Product

Resources

About